Skip to main content

Table 1 Clinical characteristics of ECMO patients

From: The effect of recombinant versus plasma-derived von Willebrand factor on prolonged PFA closure times in ECMO patients with acquired von Willebrand syndrome – an observational study

Parameter

Value

Patients

13

Age (y, IQR)

50.0 (34.5–53.5)

Female, n (%)

4 (31)

BMI (kg/m2, IQR)

31.0 (26.9-40.3)

Survivors, n (%)

10 (77)

SOFA Score (IQR)

10.0 (9.0-11.5)

Acute renal failure, n (%)

5 (38)

Dialysis, n (%)

1 (8)

Creatinine (mg/dl, IQR)

1.0 (0.6-3.4)

Urea (mg/dl, IQR)

91.0 (55.0-128.5)

Mechanical ventilation, n (%)

11 (85)

Respiratory rate (/min, IQR)

23.0 (14.5-26.5)

pH (IQR)

7.39 (7.35-7.44)

paO2 (mmHg, IQR)

70.0 (64.3-79.9)

paCO2 (mmHg, IQR)

45.6 (40.1-47.5)

Antibiotics, n (%)

8 (62)

Transfusions (Red Blood Cells), n (%)

2 (15)

COVID-19, n (%)

10 (77)

VV ECMO, n (%)

11 (85)

 - ARDS, n (%)

11 (85)

  ◦ COVID-19 associated, n (% of ARDS)

9 (82)

VA ECMO, n (%)

2 (15)

 - Pulmonary Embolism, n (%)

1 (8)

 - COVID-19 associated Perimyocarditis, n (%)

1 (8)

Type of ECMO, n (%)

 - Stöckert Sorin

7 (54)

 - Maquet

3 (23)

 - Centrimag

3 (23)

Days on ECMO (d, IQR)

1.0 (1.0-2.0)

Blood flow (l/min, IQR)

4.0 (3.1-4.8)

FiO (%, IQR) in ECMO circuit

100 (90-100)

Noradrenalin, n (%)

9 (69)

Major bleeding, n (%)

3 (23)

 - Intracerebral hemorrhage

2 (15)

Minor bleeding, n (%)

4 (31)

Heparin, n (%)

10 (77)

ASA, n (%)

1 (8)

Hemoglobin (g/dl, IQR)

9.9 (9.2-10.5)

Hematocrit (%, IQR)

29.4 (27.5-30.7)

Prothrombin time (s, IQR)

11.4 (11.0-14.1)

INR (IQR)

1.1 (1.0-1.2)

APTT (s, IQR)

48.0 (31.5-61.0)

Fibrinogen (mg/dl, IQR)

386.0 (234.0-607.5)

Platelets (x103/µl, IQR)

225.0 (133.5-264.0)

CRP (mg/l, IQR)

62.9 (36.1-245.3)

PCT (ng/ml, IQR)

1.3 (0.2-3.6)

Leukocytes (x 103/µl, IQR)

11.2 (7.6-15.0)

AST (U/l, IQR)

105.0 (44.5-190.5)

ALT (U/l, IQR)

50.0 (35.0-133.5)

Bilirubin (mg/dl, IQR)

1.1 (0.5-1.4)

Lactate (mmol/l, IQR)

1.3 (0.9-1.8)

  1. Data are presented as median (interquartile range, Q1-Q3) or number of patients (%). Denominator of the percentage is the total number of subjects in the group. Clinical and laboratory parameters from individual ECMO patients were gathered from the electronic patient data management system closest to the time point of blood sampling. Therefore, they reflect the clinical situation at the time of blood sampling. Transfusions indicates the number of patients that received transfusions on the day before blood taking (only red blood cell transfusions were given). During the time on ECMO nearly all patients required transfusions. The bleeding complications presented occurred during the total time while patients were on ECMO and not at the time of blood sampling. Days on ECMO only reflect the first 60 hours of ECMO therapy during which blood was sampled. ALT Alanine aminotransferase, ARDS Acute respiratory distress syndrome, ASA Acetylsalicylic acid, AST Aspartate aminotransferase, COVID-19 Coronavirus disease 2019, BMI Body mass index, CRP C-reactive protein, FiO Fraction of inspired oxygen, Hb Hemoglobin, INR International normalized ratio, PCT Procalcitonin, APTT Activated partial thromboplastin time, VA ECMO Veno-arterial extracorporeal membrane oxygenation, VV ECMO Veno-venous extracorporeal membrane oxygenation
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us